abcodia

Executive Summary

Abcodia is a UK-based diagnostics company dedicated to the early detection of ovarian cancer, particularly in women at high genetic risk (e.g., BRCA1/2 mutation carriers) who wish to delay prophylactic surgery. Its flagship product, the ROCA Test, is a blood-based surveillance tool that uses longitudinal CA-125 measurements to assess risk of ovarian malignancy. The test is endorsed by the UK's National Institute for Health and Care Excellence (NICE) and is offered through NHS partnerships and private clinics. Founded in 2009, the company remains private with no disclosed funding rounds or valuation, operating in a niche but clinically important segment of women's health diagnostics. Despite its NICE endorsement and established presence in the UK, abcodia faces challenges in scaling adoption beyond high-risk populations and expanding into other geographies. The ovarian cancer screening market is competitive, with emerging liquid biopsy alternatives. However, the ROCA test's unique longitudinal algorithm and strong clinical evidence could support broader reimbursement and international expansion. Key catalysts include the rollout of NHS commissioning for hereditary cancer surveillance, publication of long-term outcomes data from ongoing studies, and potential CE marking updates that could facilitate entry into European markets. Conviction in abcodia's trajectory is moderate, given its focused market and limited financial disclosure.

Upcoming Catalysts (preview)

• H2 2026Expansion of NHS commissioning for ROCA test in hereditary cancer pathways70% success
• Q4 2026Publication of long-term outcomes data from the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) follow-up study65% success
• H1 2027CE marking or UKCA certification update enabling broader commercial use in Europe50% success